Vaxart, Inc. (VXRT) stock prices were up a marginal 1.32% as of market close on April 28th, 2021, bringing the price per share up to USD$8.44. Subsequent current market fluctuations saw the price per share surge by 15.40%, bringing it up to USD$9.74.
New Covid-19 Tablet
After more than a year of the global economy have been ravaged by the effects of the COVID-19 pandemic, VXRT hopes to lead the charge to universal immunization with the development of VXA-CoV2-1. What sets the company apart from its competitors is that this drug comes in a tablet as compared to the industry standard of injection-based COVID treatments. This will help bypass concerns of costly transportation of injection-based vaccines, as well as accelerate the rate at which populations can be immunized because the administering of tablets does not require trained personnel in the way injection-based vaccines do.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Effectiveness Against Emerging Strains
A rising cause for concern has been the emergence of variant strains of COVID-19, which many fear will be resistant to the progress hitherto made on vaccines. VXA-CoV2-1 target nucleoproteins as well as spike proteins, with a significant T-cell response having been observed as a target of the N protein. With T-cell responses being linked to protection from even the more severe symptoms of COVID-19, VXRT is tapping into the drugs potential to be effective against the newer strains of the virus.
Success of Clinical Trial Phase 1
The first phase of VXA-CoV2-1 trials was a massive success, with the drug meeting its primary endpoint as well as all of its secondary endpoints. Under a recently expanded agreement with Kindred Biosciences to facilitate the development and manufacturing of COVID-19 vaccine candidates, the company’s California plant will see the scaling of clinical trial material into mid-sized bioreactors. The amendments will also see the single use bioreactors in the Kansas plant being used for manufacturing at a 2000L scale.
Partnership with Attwill Vascular Tech
VXRT recently entered an agreement with Attwill Vascular Technologies that will facilitate the processing and lyophilizing of specific compounds, as well as the tableting of the lyophilized compounds, for use in VXA-CoV2-1. In an effort to sustain these developments the company has increased its headcount to 49 full-time employees, with hiring having been primarily conducted in R7d, clinical, regulatory, manufacturing, and financial areas.
Future Outlook for VXRT
The resounding success of the first phase of VXA-CoV2-1’s clinical trial has boosted investor confidence as the company prepares for the second phase of trials. In conjunction with strong strategic partnership and a solid liquidity position, the company is poised to leverage its resources to stay at the forefront of the race for universal immunization. Both current and prospective shareholders are hopeful for the future of the company, as evidence by recent surges in VXRT stock prices.